Compare like-for-like revenue
The annual revenue series records USD 3.29bn for the period ended September 30, 2026. That is 3.6% below the same reporting basis a year earlier.
—
—
—
Scotts Miracle-Gro
—
—
Live Price
CIN RESEARCH · DATED EVIDENCE
Dated financial evidenceScotts Miracle-Gro: revenue contracted; examine the operating evidence.
The annual revenue series records USD 3.29bn for the period ended September 30, 2026. That is 3.6% below the same reporting basis a year earlier. Cash and operating cash flow are available on a matching dated basis.
Latest financial observation 2026-09-30Last reported price 2026-11-06Research checked 2026-11-07 13:31 UTC
The check time records a research refresh. Each financial figure and price keeps its own reporting date.
Read the bottom-line result
The matching annual net income is USD 103.9m. This is the reported result for 2026-09-30, not a future earnings estimate.
Put cash beside operating cash flow
Period-end cash was USD 7.4m at 2026-09-30. The matching annual operating cash inflow was USD 373m. Later financing and cash movements are not established by this snapshot.
Follow the primary disclosures
The available record includes 1 primary disclosure. The latest is 2026-07-01. This is the available feed record, not a claim of complete filing coverage.
Reported financial evidence
| Measure | Reported value & unit | Period & interval | Evidence basis |
|---|---|---|---|
| Revenue | USD 3.29bnUnit: USD | Annual period | Dated financial series |
| Cost of revenue | USD 2.23bnUnit: USD | Annual period | Dated financial series |
| Gross profit | USD 1.06bnUnit: USD | Annual period | Dated financial series |
| Operating income | USD 406.7mUnit: USD | Annual period | Dated financial series |
| EBITDA | USD 458.5mUnit: USD | Annual period | Dated financial series |
| Net income | USD 103.9mUnit: USD | Annual period | Dated financial series |
| Cash balance | USD 7.4mUnit: USD | Balance at period end | Dated financial series |
| Total assets | USD 2.74bnUnit: USD | Balance at period end | Dated financial series |
| Total liabilities | USD 3.11bnUnit: USD | Balance at period end | Dated financial series |
| Shareholders’ equity | USD -372.4mUnit: USD | Balance at period end | Dated financial series |
| Operating cash flow | USD 373mUnit: USD | Annual period | Dated financial series |
| Free cash flow | USD 278.4mUnit: USD | Annual period | Dated financial series |
A balance at period end is not income over a period. “Quarterly series” follows the available classification; the source disclosure establishes the actual reporting interval.
What changed against the prior year
Only the same measure, unit, reporting frequency and prior-year period end are compared. A reported change is not an investment rating.
Decreased -3.6%
- 2025-09-30
- USD 3,413,100,000
- 2026-09-30
- USD 3,288,900,000
Decreased -6%
- 2025-09-30
- USD 2,368,900,000
- 2026-09-30
- USD 2,225,900,000
Increased +1.8%
- 2025-09-30
- USD 1,044,200,000
- 2026-09-30
- USD 1,063,000,000
Increased +13.4%
- 2025-09-30
- USD 358,600,000
- 2026-09-30
- USD 406,700,000
Increased +7.8%
- 2025-09-30
- USD 425,500,000
- 2026-09-30
- USD 458,500,000
Decreased -28.4%
- 2025-09-30
- USD 145,200,000
- 2026-09-30
- USD 103,900,000
Increased +0.5%
- 2025-09-30
- USD 371,300,000
- 2026-09-30
- USD 373,000,000
Increased +1.6%
- 2025-09-30
- USD 273,900,000
- 2026-09-30
- USD 278,400,000
What to investigate next
- Resolve the conflicting financial observations against the primary report.
- Read the latest linked company disclosures and any reporting after the financial period.
- Check post-period financing, share issuance and changes in cash before drawing a current valuation conclusion.
Evidence boundaries
- Conflicting observations for the same concept, period and reporting basis are withheld.
- The earlier rating is not presented as a current conclusion. This report is rebuilt from dated evidence.
Primary company disclosures
Independent evidence summary. No broker consensus, price target or investment rating is manufactured. Research standards →
Price History · USD
5 Years
Fundamentals
SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
CONTINUE YOUR RESEARCH